Imperial College London

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Private

Established: 1907-07-08

Employees: 5K

Market Cap: -

Website: http://www.imperial.ac.uk

Clinical Trials

In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma

Early Phase 1

Completed

Conditions: Asthma

Interventions: Drug: VR588

First Posted Date: 2016-04-15

Last Posted Date: 2019-10-28

Lead Sponsor: Imperial College London

Target Recruit Count: 9

Registration Number: NCT02740049

Locations: 🇬🇧
Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom

A Study of Prolonged Electrocardiographic Monitoring in Patients With Heart Failure in Sinus Rhythm or Atrial Fibrillation

Completed

Conditions: Atrial Fibrillation
Heart Failure

Interventions: Other: no intervention

First Posted Date: 2016-03-14

Last Posted Date: 2023-07-27

Lead Sponsor: Imperial College London

Target Recruit Count: 100

Registration Number: NCT02707744

Locations: 🇬🇧
Northwick Park Hospital, London, United Kingdom
🇬🇧
Greater Glasgow and Clyde, Glasgow, United Kingdom
🇬🇧
Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom

Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial

Not Applicable

Recruiting

Conditions: Rectal Cancer

Interventions: Diagnostic Test: High resolution MRI scan
Diagnostic Test: mrTRG assessment

First Posted Date: 2016-03-10

Last Posted Date: 2024-10-17

Lead Sponsor: Imperial College London

Target Recruit Count: 441

Registration Number: NCT02704520

Locations: 🇬🇧
University Hospital of North Tees, Stockton-on-Tees, United Kingdom
🇬🇧
Colchester General Hospital, Colchester, United Kingdom
🇬🇧
NHS Lanarkshire - Hairmyres Hospital, East Kilbride, United Kingdom

and more 7 locations

Exhaled Hydrogen Sulphide as a Biomarker of Airways Disease in Asthma

Completed

Conditions: Asthma

First Posted Date: 2016-03-09

Last Posted Date: 2019-10-21

Lead Sponsor: Imperial College London

Target Recruit Count: 70

Registration Number: NCT02703467

Locations: 🇬🇧
Royal Brompton Hospital, London, United Kingdom

Study of the Gut Hormone Analogue G3215 in Adult Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus
Obesity

Interventions: Drug: G3215
Drug: Placebo

First Posted Date: 2016-02-25

Last Posted Date: 2020-12-23

Lead Sponsor: Imperial College London

Target Recruit Count: 90

Registration Number: NCT02692040

Locations: 🇬🇧
Covance Clinical Research Unit, Leeds, United Kingdom

Gut Hormones in Obesity, Nicotine and Alcohol Dependence

Early Phase 1

Conditions: Alcoholism
Smoking Cessation
Obesity

Interventions: Drug: Exenatide
Biological: Desacyl ghrelin
Biological: Saline

First Posted Date: 2016-02-24

Last Posted Date: 2020-02-13

Lead Sponsor: Imperial College London

Target Recruit Count: 95

Registration Number: NCT02690987

Locations: 🇬🇧
Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, Hammersmith Hospital, London, United Kingdom

Airway Effects of Tiotropium in Patients With COPD

Phase 3

Completed

Conditions: COPD
LUNG DISEASES, OBSTRUCTIVE

Interventions: Combination Product: Handihaler-Tiotropium 18 mcg untrained
Combination Product: Handihaler-Tiotropium 18 mcg trained
Combination Product: Respimat-Tiotropium 5 mcg trained

First Posted Date: 2016-02-17

Last Posted Date: 2019-11-12

Lead Sponsor: Imperial College London

Target Recruit Count: 44

Registration Number: NCT02683668

Locations: 🇬🇧
Asthma Lab, Royal Brompton Hospital, London, United Kingdom

Intelligent Oxygen Therapy During Activities of Daily Living

Not Applicable

Completed

Conditions: Hypoxia
COPD
Hyperoxia

Interventions: Device: Long-term oxygen therapy
Device: Intelligent oxygen therapy (an auto-titrating oxygen system)

First Posted Date: 2016-02-17

Last Posted Date: 2023-11-29

Lead Sponsor: Imperial College London

Target Recruit Count: 25

Registration Number: NCT02683486

Locations: 🇬🇧
Royal Brompton and Harefield NHS Trust, London, United Kingdom

ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Eribulin

First Posted Date: 2016-02-12

Last Posted Date: 2021-02-05

Lead Sponsor: Imperial College London

Target Recruit Count: 8

Registration Number: NCT02681523

Locations: 🇬🇧
Charing Cross Hopsital, London, United Kingdom

The His Optimised Pacing Evaluated for Heart Failure Trial (HOPE-HF).

Not Applicable

Completed

Conditions: Heart Failure

First Posted Date: 2016-02-02

Last Posted Date: 2020-12-03

Lead Sponsor: Imperial College London

Target Recruit Count: 198

Registration Number: NCT02671903

Locations: 🇬🇧
Basildon and Thurrock Hospitals NHS Foundation Trust, Basildon, United Kingdom
🇬🇧
University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
🇬🇧
Western Sussex Hospitals NHS Foundation Trust, Chichester, United Kingdom

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy